**Core Concept**
The question is testing the understanding of the pharmacological properties of second-generation antipsychotics (SGAs), specifically their mechanism of action and dose-dependent effects. SGAs are known for their lower risk of extrapyramidal side effects (EPS) compared to first-generation antipsychotics (FGAs), but some SGAs can exhibit FGA-like properties at higher doses.

**Why the Correct Answer is Right**
Risperidone is a SGA that can exhibit FGA-like properties at high doses. This is due to its partial agonism of the dopamine D2 receptor, which is similar to the mechanism of action of FGAs. At lower doses, risperidone primarily acts as a serotonin-dopamine antagonist, but at higher doses, its D2 receptor antagonism becomes more pronounced, leading to increased risk of EPS. This property makes risperidone unique among SGAs and allows it to function as a FGA in large doses.

**Why Each Wrong Option is Incorrect**
**Option A:** Olanzapine is another SGA, but it does not exhibit FGA-like properties at high doses. Its mechanism of action is primarily as a serotonin-dopamine antagonist, and it does not have significant D2 receptor antagonism.
**Option B:** Quetiapine is a SGA that is primarily used for treating depressive symptoms in patients with bipolar disorder. It does not exhibit FGA-like properties at high doses and is not known for its D2 receptor antagonism.
**Option C:** Ziprasidone is a SGA that is primarily used for treating schizophrenia. It does not exhibit FGA-like properties at high doses and is known for its rapid onset of action and minimal risk of EPS.

**Clinical Pearl / High-Yield Fact**
When using SGAs, it's essential to be aware of their potential for dose-dependent effects, including FGA-like properties. Risperidone's unique pharmacology makes it a good option for patients who require higher doses of antipsychotic medication, but its use should be carefully monitored for EPS.

**Correct Answer:** C.